Ileal transposition in surgical treatment for type 2 diabetes mellitus

High prevalence and insufficient efficacy of medical treatment in type 2 diabetes mellitus (T2DM) poses a major challenge for medical care. Generally, only 30% of patients reach therapeutic goals, while remission occurs only in the minority of patients. In the obese (BMI>35 kg/m2), bariatric surg...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Oleg Viktorovich Kornyushin, Mikhail Michailovich Galagudza, Alexander Evgen'evich Neymark, Alina Yur'evna Grineva, Elena Nikolaevna Babenko
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2015
Materias:
Acceso en línea:https://doaj.org/article/f2ec8cab73f34f0b943233c65732d453
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:High prevalence and insufficient efficacy of medical treatment in type 2 diabetes mellitus (T2DM) poses a major challenge for medical care. Generally, only 30% of patients reach therapeutic goals, while remission occurs only in the minority of patients. In the obese (BMI>35 kg/m2), bariatric surgery provides an alternative to pharmacological treatment of T2DM, boosting remission/compensation rate up to 76.8%. A few recent clinical studies explored the anti-diabetic effect of ileal transposition (IT). This type of surgery targets restoration of incretin balance by proximal transposition of ileal segment. In this review, we discuss the salutary mechanisms of IT in T2DM based on the analysis of the pioneering clinical trials.